DeepMed Research

Primaquine

Generic Name: Primaquine

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁N_₃O

CAS Number: 90-34-6

Unique Ingredient Identifier: MVR3634GX1

Background: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)

Indication: For the treatment of malaria.

Associated Conditions: Malaria, Malaria caused by Plasmodium ovale, Malaria caused by plasmodium vivax, Pneumocystis Jirovecii Pneumonia

Clinical Trials

Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: OZ439
Drug: Primaquine

First Posted Date: 2015-05-01

Last Posted Date: 2020-05-26

Lead Sponsor: Medicines for Malaria Venture

Target Recruit Count: 11

Registration Number: NCT02431650

Locations: 🇦🇺
Q-Pharm Clinics, Herston, Queensland, Australia

Effectiveness of Malaria Treatment in Mexico

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Chloroquine phosphate
Drug: primaquine

First Posted Date: 2015-03-20

Last Posted Date: 2015-03-20

Lead Sponsor: LILIA GONZALEZ CERON

Target Recruit Count: 153

Registration Number: NCT02394197

A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh

Phase 4

Completed

Conditions: Malaria

Interventions: Drug: Artemether-lumefantrine combination
Drug: chloroquine
Drug: Primaquine

First Posted Date: 2015-03-17

Last Posted Date: 2024-03-13

Lead Sponsor: Menzies School of Health Research

Target Recruit Count: 181

Registration Number: NCT02389374

Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection

Phase 4

Conditions: Plasmodium Vivax

Interventions: Drug: Primaquine

First Posted Date: 2015-02-18

Last Posted Date: 2015-10-14

Lead Sponsor: Papua New Guinea Institute of Medical Research

Target Recruit Count: 150

Registration Number: NCT02364583

Locations: 🇵🇬
PNG Institute of Medical Research, Madang, Madang Province, Papua New Guinea

Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia

Phase 3

Conditions: Plasmodium Vivax Malaria Without Complication

Interventions: Drug: Artemether-lumefantrine + Primaquine
Drug: Chloroquine + Primaquine

First Posted Date: 2015-01-28

Last Posted Date: 2017-02-01

Lead Sponsor: Menzies School of Health Research

Target Recruit Count: 98

Registration Number: NCT02348788

Locations: 🇲🇾
Pitas District Hospital, Pitas, Sabah, Malaysia
🇲🇾
Kudat District Hospital, Kudat, Sabah, Malaysia
🇲🇾
Kota Marudu District Hospital, Kota Marudu, Sabah, Malaysia

Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission

Phase 3

Completed

Conditions: Malaria
Asymptomatic Malaria
Plasmodium Falciparum

Interventions: Drug: Dihydroartemisinin-piperaquine combination (Artekin)
Drug: Primaquine

First Posted Date: 2014-10-08

Last Posted Date: 2016-01-14

Lead Sponsor: London School of Hygiene and Tropical Medicine

Target Recruit Count: 120

Registration Number: NCT02259426

Locations: 🇰🇪
ICIPE, Mbita, Nyanza, Kenya

Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria

Phase 3

Completed

Conditions: Malaria, Vivax

Interventions: Drug: Tafenoquine Placebo
Drug: Tafenoquine
Drug: Chloroquine
Drug: Primaquine Placebo
Drug: Primaquine

First Posted Date: 2014-08-13

Last Posted Date: 2018-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 251

Registration Number: NCT02216123

Locations: 🇻🇳
GSK Investigational Site, Ho Chi Minh, Vietnam

Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Phase 4

Completed

Conditions: Plasmodium Vivax Infection
Plasmodium Vivax Clinical Episode
Plasmodium Falciparum Infection
Plasmodium Falciparum Clinical Episode

Interventions: Drug: Placebo
Drug: Primaquine
Drug: Chloroquine
Drug: Artemether Lumefantrine

First Posted Date: 2014-05-21

Last Posted Date: 2014-05-21

Lead Sponsor: Papua New Guinea Institute of Medical Research

Target Recruit Count: 524

Registration Number: NCT02143934

Locations: 🇵🇬
PNG Institute of Medical Research, Maprik, East Sepik Province, Papua New Guinea

Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes

Phase 4

Completed

Conditions: Plasmodium Falciparum

Interventions: Drug: Primaquine (For artemether-lumefantrine+primaquine arm)
Drug: Placebo (For artemether-lumefantrine arm)

First Posted Date: 2014-03-18

Last Posted Date: 2014-12-08

Lead Sponsor: Muhimbili University of Health and Allied Sciences

Target Recruit Count: 220

Registration Number: NCT02090036

Locations: 🇹🇿
Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania

Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil

Not Applicable

Completed

Conditions: Malaria

Interventions: Drug: Chloroquine
Drug: Primaquine

First Posted Date: 2014-01-23

Last Posted Date: 2018-02-07

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 119

Registration Number: NCT02043652

Locations: 🇧🇷
Hospital do Jurua, Cruzeiro do Sul, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy